reSETTM AS A TREATMENT TOOL FOR SUBSTANCE USE DISORDER
reSETTM demonstrates improved abstinence and treatment retention when used in conjunction with face-to-face therapy to treat SUD related to stimulants, marijuana, cocaine and alcohol
- 507 patients with SUD across 10 treatment centers nation-wide were randomized to receive either face-to-face therapy, or a reduced amount of face-to-face therapy plus reSETTM.
- Patients received 12 weeks of typical outpatient treatment with or without reSETTM (reSETTM was substituted for a portion of face-to-face therapy).
- Abstinence was measured twice weekly via urine analysis, breathalyzer, and self-reports.
- In patients who were dependent on stimulants, marijuana, cocaine, or alcohol (n=395), 58.1% of patients receiving reSETTM were abstinent in study weeks 9-12, while 29.8% of patients receiving face-to-face therapy alone were abstinent during the same time frame (p<0.01).
- Participants who tested positive for drug use at the start of the study (n=191), 26.7% of patients receiving reSETTM were abstinent in study weeks 9-12, while 3.2% of patients receiving traditional face-to-face therapy were abstinent during the same time frame (p<0.01).
Patients Non-Abstinent at Baseline
- Treatment retention is a positive predictor of future, positive outcomes such as decrease in drug use1-3.
- Patients receiving reSETTM showed statistically significant improvement in retention compared to face-to-face therapy alone (p=0.0051). At the end of 12 weeks of treatment 61% of patients receiving face-to-face therapy were retained in the study compared to 70% of patients receiving reSETTM.
1. Hubbard et al. Psychol Addict Behav. 1997.
2. Simpson. Am J Psychiatry. 1979.
3. Zhang et al. Addiction. 2003.
ClinicalTrials.gov Identifier: NCT01104805